UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

Date of Report: September 22, 2021

Commission File Number: 001-39307

Legend Biotech Corporation

(Exact Name of Registrant as Specified in its Charter)

2101 Cottontail Lane

Somerset, New Jersey 08873

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

Legend Biotech to Host R&D Day on October 18, 2021

Legend Biotech Corporation (“Legend Biotech”) will host its first Research & Development Day on Monday, October 18, 2021, commencing at 10:00 a.m. (Eastern time).  A live webcast will be available to investors and other interested parties by accessing the Legend Biotech website at https://investors.legendbiotech.com/events-and-presentations.

EXHIBIT INDEX

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Exhibit 99.1

Legend Biotech to Host R&D Day on October 18, 2021

SOMERSET, N.J.--(BUSINESS WIRE)--September 22, 2021--Legend Biotech Corporation (NASDAQ: LEGN), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, will host its first Research & Development Day on Monday, October 18, commencing at 10:00 a.m. (Eastern Time), at Andaz 5^th^ Avenue in New York.

The meeting will feature updates on the company’s advancing pipeline of hematological and oncological indications and expanding cell therapy capabilities, including its B cell maturation antigen (BCMA) clinical development program. Presentations will be delivered by Legend’s senior leadership team:

• Ying Huang, PhD, Chief Executive Officer and Chief Financial Officer
• Frank Fan, MD, PhD, Chief Scientific Officer
• Steve Gavel, Vice President, US & Europe Commercial
• Lida Pacaud, MD, Vice President, Clinical Development

A live webcast and presentation will be available to investors and other interested parties on the Legend Biotech website under “Events and Presentations”. A recording of the webcast can be viewed as early as 24 hours after the event and will be archived for six months.

To register for the event, please visit this link.

About Legend Biotech

Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our team of over 900 employees across the United States, China and Europe, along with our differentiated technology, global development, and manufacturing strategies and expertise, provide us with the strong potential to discover, develop, and manufacture best-in-class cell therapies for patients in need. We are engaged in a strategic collaboration to develop and commercialize our lead product candidate, cilta-cel, an investigational BCMA-targeted CAR-T cell therapy for patients living with multiple myeloma. This candidate is currently being studied in registrational clinical trials.

Contacts

Investor Contacts:

          Jessie Yeung, Head of Corporate Finance and Investor Relations, Legend Biotech 

          jessie.yeung@legendbiotech.com or investor@legendbiotech.com

Crystal Chen, Manager of Investor Relations and Corporate Communications, Legend Biotech

          crystal.chen@legendbiotech.com

Press Contact:

          Tina Carter, Corporate Communications Lead, Legend Biotech 

          tina.carter@legendbiotech.com

          \(908\) 331-5025